Memantine with or without raloxifene to help protect memory during brain radiation
Official title: Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests whether adding a second drug helps delay memory problems during brain radiation.
Read our full plain-language summary
What the trial team says
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.
Key facts
- Registry number
- NCT07470606
- Stage of testing
- Phase 2
- Conditions studied
- Brain Tumor
Where it is running
This trial lists 1 site.
-
Texas
- Mays Cancer Center, UT Health San Antonio (San Antonio)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.